 Today I have the pleasure of speaking with Steve Saviak from Vallejo Pharma. Steve, how are you today? Very good, Tracy. Nice to be back. So you just put out, you're putting out, you've got just a magnanimous news flow of real news, Steve. So it's really nice to get an update from you. And just this last week, you announced a deal with Montreal Heart Institutes with a hasperidin coronavirus clinical trial. But this is the part of the news release we liked. You said that your study will evaluate the effect of hasperidin on COVID-19 symptoms and its ability to reduce disease, severity, and the need for hospitalization in patients. Okay, tell us about this news release, please. Well, we've been researching hasperidin in particular with a small biotech company at Montreal for the last nine months, 10 months. We came up with a formulation. The Institute was presented with all the clinical background data, 20 years worth of data. They really liked what they saw. They liked the fact that this is a natural product, that this has not had very good safety profile, but very interesting potential efficacy. And as a result of this significant literature review, they decided to undertake the trial. We manufactured the product for them. It's a spherical capsules and the trial kicked off yesterday. And you'll start seeing it more in social media coming in the days to follow as they start recruiting patients for the trial. So there's a lot of competitors out there so much so that we were discussing Twitter prior to this actual interview that Twitter literally and Google are blocking a lot of announcements having to do with COVID-19 even though there's some really amazing companies that are out there. So getting your story out there with this particular challenge is kind of, you know, how are you dealing with it? Well, you're dead right on that. There's been so many molecules put forward as potentially helping or reducing or curing or what have you. I think we have to look at the fact that the Montreal Heart Institute is a leading institute. They've done a number of trials, a number of trials even with COVID and for them to continue to be interested in what is really a fairly simple molecule and we actually call it a medicinal ingredient on our packaging is testament to the many hours of research that independent researchers from around the world have done demonstrating that asperidine could have a very positive effect on patients that are symptomatic with COVID-19. So I think this is, you know, we're not saying that other products are better beneficial can be used or what have you. We're saying this is a safe potential treatment for or reducing the symptoms of coronavirus. In addition, it's great immune support product. That's just core value, no side effects, a dollar a day. Don't need a prescription. You can get it at your pharmacy and it has a lot of benefits for patients that feel that their immune system needs some protection and some assistance. All right, so we talked to with all those Reddit investors, we got a lot of young people, our website numbers are going through the roof and they're going, you know, and I'm saying, okay, you know, you have to take some time to research the company that you're buying the shares for and you need to be evaluating, you know, looking at their market valuation. Can you comment to our audience out there about your current market valuation and where your share price is and how you feel about that presently? Yeah, well, you know, as much as we've talked about Asperico, Asperico is not the only product that we have and it's probably not going to even be the biggest product that we have. We expect to launch a product in early May called Redesca, which is a blood thinner and has a, we believe, great market potential, 30 plus million, 40 plus million type top line revenues. Our market cap today is somewhere between 65 and 70 million and I think what that does not reflect is the future. So I'll use the hockey analogy that I think our great Wayne Gretzky put forward. Don't look where the puck is, look where the puck's going. The same thing, you can't look at our valuation today and look at our revenues today. Our revenues are slated to almost triple in the current fiscal year, which ends October 21st. And I think you have to say, well, what will the valuation be as these revenues become realized and as we're able to announce improving quarterly revenues and earnings. And I think that's what investors have to look at as a future, not so much the past or the present. Well, having watched a lot of hockey, I think understanding where that puck is going is not my area of expertise. However, one of our analysts wrote revenue forecasters to triple just like you just said as Vallejo benefits from last year's successes. When should we anticipate our next revenue updates or quarterly updates for all those shareholders out there that are watching Vallejo Pharma and for some new ones that are putting you on their grid? Well, we'll be presenting our announcing our fourth quarter and annual revenues. Again, we have an October year in. We'll be doing so next Wednesday. Then the first quarter will be coming out several weeks after. I think where you'll see the real revenue jump, it will start in the second quarter. The first quarter is going to be a good quarter, but the second quarter you'll see that real demarcation from our past. So last year's gross, top line gross was about 8.5 million or so. This year we're looking at somewhere as 20, 25 million. It's always difficult in COVID. It does affect the pharma industry, but it's affected many industries. But we have a very strong feeling about this growth and it's principally from the growth of our existing products, as well as Asperko, Redesco, which will be launching and potentially some other products that could come on board later on this summer. Okay. Well, we're following Redesco. Redesco, is that correct? I pronounced it correct? Yeah. So you just also, I mean, you do put out regular news releases and they're crunchy, real good news. So you also just put out the last couple of weeks that Redesco receives positive recommendation for public reimbursement in Quebec. Would you like to give us an update on that? Yeah. Well, the, you know, what people or your viewers need to sort of accept or understand is that drugs are, you know, help a lot of diseases, but someone has to pay for these drugs. And typically it's one of two pairs. It's a private insurance companies. If you're working for a company that has a private plan or it's the public, the provincial governments themselves. And roughly the market is split 50-50 between the two. So it's very important to get the provinces to agree to pay for a drug. Redesco is the type of drug that will save the Canadian healthcare system quite a bit of dollars. It's called a biosimilar. So it's similar to an existing biological drug. And the, this first Quebec acceptance is the first of what we expect to be 10 all across Canada. Quebec, in this case, had to be the first mover. We're based in Quebec. But the report itself talks a lot about how good of a dossier manufacturing efficacy of the drug. And we expect that to continue, as I said, across Canada. And it's a critical, critical step in any drug's commercial success in Canada is to get provincial reimbursement. And so to get it early as we have and the interactions we're having with the other provinces, very favourable. And I think this bodes well for the launch of Redesco in sort of the end of the spring. Well, Steve, will you do me a favour and do an update with us at Investor Intel at least once a month, once every other six weeks so we can make sure our investors are following you. Because I'm sure there's a lot of people out there that will be surprised to know that last year you had a 230% stock price gain. They're going to want to make sure that they're following you, trying to keep up with you. Make sure we know where that hockey puck is headed. Tracy, I promise you we will. It's always a pleasure to be on your program and to talk to your investor base. And we look forward to being back shortly. Thank you so much for joining us today, Steve.